Christopher P. Acevedo

Form D signer

Christopher P. Acevedo

Chief Financial Officer at OS Therapies

Form D signer

Capital raised by OS Therapies

$11.6M+$1.6M latest round

4 Form D filings · first filed Jun 2025 · Grasonville, MD

CURRENT ROLE: Chief Financial Officer
SECTOR: Biotech
COMPANY FILINGS: 4
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

OS TherapiesBiotech · Grasonville, MDsince Jun 2025

Chief Financial Officer

Signatory on OS Therapies's Form D filings · $11.6M raised across 4

Company filings

via EDGAR · Form D for OS Therapies4

DateCompanyFormAmountRole on filing

Jun 30, 2026OS TherapiesForm D+$1.6MChief Financial Officer

Form DJun 30, 2026 · OS Therapies+$1.6Mas Chief Financial Officer

Mar 4, 2026OS TherapiesForm D+$2.0MChief Financial Officer

Form DMar 4, 2026 · OS Therapies+$2.0Mas Chief Financial Officer

Sep 2, 2025OS TherapiesForm D+$3.8MChief Financial Officer

Form DSep 2, 2025 · OS Therapies+$3.8Mas Chief Financial Officer

Jun 23, 2025OS TherapiesForm D+$4.2MChief Financial Officer

Form DJun 23, 2025 · OS Therapies+$4.2Mas Chief Financial Officer

Overview

Last filing Jun 30, 2026

Christopher P. Acevedo is on file as Chief Financial Officer at OS Therapies in Grasonville, MD. OS Therapies has 4 Form D filings on record, $11.6M raised in total. Christopher P. Acevedo appears as a signatory on the company's filings.

Teammates

OS Therapies · 1

Theodore SearchDirector

Products

OS Therapies · 1

Lead Immunotherapy CandidateClinical-Stage Immunotherapy

The company's flagship product is an immunotherapy drug currently in human clinical trials. It is engineered to activate the body's immune system to recognize and eliminate cancer cells that express the HER2 protein, with an initial indication for osteosarcoma and potential application across other solid tumors.